Lara Sullivan - Net Worth and Insider Trading

Lara Sullivan Net Worth

The estimated net worth of Lara Sullivan is at least $10 Million dollars as of 2024-05-16. Lara Sullivan is the President and CEO of Pyxis Oncology Inc and owns about 2,403,882 shares of Pyxis Oncology Inc (PYXS) stock worth over $10 Million. Details can be seen in Lara Sullivan's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Lara Sullivan has not made any transactions after 2023-09-18 and currently still holds the listed stock(s).

Transaction Summary of Lara Sullivan

To

Lara Sullivan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Lara Sullivan owns 3 companies in total, including Rexahn Pharmaceuticals Inc (REXN) , Ocuphire Pharma Inc (OCUP) , and Pyxis Oncology Inc (PYXS) .

Click here to see the complete history of Lara Sullivan’s form 4 insider trades.

Insider Ownership Summary of Lara Sullivan

Ticker Comapny Transaction Date Type of Owner
REXN Rexahn Pharmaceuticals Inc 2019-06-06 director
OCUP Ocuphire Pharma Inc 2019-02-27 director
PYXS Pyxis Oncology Inc 2023-09-18 director & Chief Executive Officer

Lara Sullivan Latest Holdings Summary

Lara Sullivan currently owns a total of 1 stock. Lara Sullivan owns 2,403,882 shares of Pyxis Oncology Inc (PYXS) as of September 18, 2023, with a value of $10 Million.

Latest Holdings of Lara Sullivan

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PYXS Pyxis Oncology Inc 2023-09-18 2,403,882 4.17 10,024,188

Holding Weightings of Lara Sullivan


Lara Sullivan Form 4 Trading Tracker

According to the SEC Form 4 filings, Lara Sullivan has made a total of 2 transactions in Pyxis Oncology Inc (PYXS) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Pyxis Oncology Inc is the sale of 8,641 shares on September 18, 2023, which brought Lara Sullivan around $18,146.

Insider Trading History of Lara Sullivan

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Lara Sullivan Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Lara Sullivan Ownership Network

Ownership Network List of Lara Sullivan

No Data

Ownership Network Relation of Lara Sullivan


Lara Sullivan Owned Company Details

What does Rexahn Pharmaceuticals Inc do?

Who are the key executives at Rexahn Pharmaceuticals Inc?

Lara Sullivan is the director of Rexahn Pharmaceuticals Inc. Other key executives at Rexahn Pharmaceuticals Inc include Chief Medical Officer Ely Benaim , Chief Business Officer Lisa Nolan , and director & President and CEO Douglas J Swirsky .

Rexahn Pharmaceuticals Inc (REXN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Rexahn Pharmaceuticals Inc (REXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Rexahn Pharmaceuticals Inc (REXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Rexahn Pharmaceuticals Inc (REXN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Rexahn Pharmaceuticals Inc Insider Transactions

No Available Data

Lara Sullivan Mailing Address

Above is the net worth, insider trading, and ownership report for Lara Sullivan. You might contact Lara Sullivan via mailing address: C/o Rexahn Pharmaceuticals, Inc., 15245 Shady Grove Road, Suite 455, Rockville Md 20850.

Discussions on Lara Sullivan

No discussions yet.